RHB-102 (Bekinda®), an investigational drug, is a proprietary bimodal immediate and extended-release, once-daily oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist.
RHB-102 is in development for several gastrointestinal indications:
Our Collaborations for RHB-102:
On February 25, 2025, RedHill announced it entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, for RHB-102 with Hyloris Pharmaceuticals SA.
* Bekinda® is the proposed tradename for RHB-102, which is subject to review by the FDA at the time of NDA filing